Sunil Kumar/LinkedIn
Dec 17, 2025, 23:37
Sunil Kumar: Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024)
Sunil Kumar, Entrepreneur of Medifit Devices LLP, shared a post on LinkedIn:
“Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024).
Rare diseases may affect smaller patient populations, but strong science, high unmet need, and long term therapy adoption continue to translate into meaningful revenues. From enzyme replacement therapies to advanced coagulation factors, these products underline the commercial strength of rare disease portfolios.
The list highlights reported 2024 revenues along with primary approved indications across areas such as amyloidosis, hemophilia, and inherited metabolic disorders.”
Stay updated with Hemostasis Today.
-
May 15, 2026, 10:48Ahmed Elshahat: Thrilled to Share Our Latest Paper on Opioid Overdose and Cardiovascular Mortality
-
May 15, 2026, 10:47Fouad Al-Noor: Congratulations to NBCA on This Landmark VTE Prevention Victory
-
May 15, 2026, 10:41Faisal Almutairi: Blood Components Overview
-
May 15, 2026, 10:29Connie Montgomery: Every Patient Deserves Representation in Clinical Research
-
May 15, 2026, 10:28Arjun Law: Transplant Should Always Be a Consideration for Severe AA Irrespective of Donor
-
May 15, 2026, 09:45Finding the Right Balance in Hemophilia Treatment – Global Hemophilia Report
-
May 15, 2026, 09:28Abel Hailu: A New Chapter for Pediatric Oncology and Hematology Care in Ethiopia
-
May 15, 2026, 09:26Abdul Mannan: Does Pregnancy Cause Aplastic Anaemia?
-
May 15, 2026, 09:20Join the Global Conversation on Health Equity in Bleeding Disorders – WFH